1. In Vivo

Dealmaking Quarterly Statistics, Q1 2023

A Look At M&A And Alliance Activity Across The Biopharma, Medical Device And In Vitro Diagnostics Industries, January-March 2023

 
• By Deanna Kamienski and Maureen Riordan

During Q1, biopharma merger and acquisition deal value reached $51.9bn and drew in $38.1bn in potential deal value from alliances. Device company M&A values reached $4.8bn, while in vitro diagnostics and research tools players’ M&A activity totaled $2.7bn.

Qstats Image 1
• Source: Alamy

Biopharma merger and acquisition value for the opening quarter of 2023 reached $51.9bn from 32 transactions, 13 of which had disclosed values. Making up 83% of that total is Pfizer’s proposed $43bn buy of Seagen This deal and four other transactions were the only M&As to hit or exceed the billion-dollar mark during Q1 (see Exhibit 1).

The proposed Pfizer/Seagen deal – which marks the largest M&A of the quarter – is expected to close in late 2023 or early 2024. Founded in 1997, Seagen uses its...

More from Deal-Making

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By Jo Shorthouse

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By Jo Shorthouse

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By David Wild

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.